Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Agenus ( (AGEN) ) has provided an update.
On October 8, 2025, Agenus Inc. entered into a Promissory Note Agreement with Zydus Pharmaceuticals (USA) Inc. for up to $10 million. The Note will fund operational expenses for Agenus’s Emeryville and Berkeley facilities in the fourth quarter of 2025, with potential forgiveness if certain agreements close. Agenus pledged shares of MiNK Therapeutics as collateral, with provisions for release upon fulfillment of the Note’s obligations.
The most recent analyst rating on (AGEN) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.
Spark’s Take on AGEN Stock
According to Spark, TipRanks’ AI Analyst, AGEN is a Neutral.
Agenus’s overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and financial instability. Technical analysis provides mixed signals, with some long-term support but short-term bearish trends. Valuation metrics further highlight financial distress, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on AGEN stock, click here.
More about Agenus
Agenus Inc. operates in the biotechnology industry, focusing on the development of immuno-oncology products and therapies.
Average Trading Volume: 688,571
Technical Sentiment Signal: Sell
Current Market Cap: $135.4M
Find detailed analytics on AGEN stock on TipRanks’ Stock Analysis page.